Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing a deal to acquire psychedelic drugmaker AtaiBeckley, triggering a sharp surge in the company's stock price.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly is reportedly close to an agreement to purchase AtaiBeckley, a company specializing in psychedelic drugs. Following reports of the buyout talks, AtaiBeckley shares experienced significant gains in after-hours trading.
Coverage from Bloomberg and Reuters emphasizes the proximity of the deal. Market-focused reports from Seeking Alpha and TradingView highlight the stock's volatility, noting price increases between 59% and 66%.
Future developments depend on the formalization of the buyout talks. Coverage does not yet specify the final terms or the official confirmation of the deal from the companies involved.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
Which company is seeking to acquire AtaiBeckley?
Eli Lilly is reported to be nearing a deal to buy the company.
How has AtaiBeckley's stock reacted to the news?
Shares soared between 59% and 66% in after-hours trading according to TradingView and Seeking Alpha.
Which news outlets first reported the potential deal?
The deal was reported by Bloomberg News and subsequently covered by Reuters.
Coverage (9)
- This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks Barron's · 3h ago
- Why Is ATAI Stock Soaring 59% After-Hours? TradingView · 3h ago
- Psychedelic drugmaker AtaiBeckley shares soar 66% on Eli Lilly buyout talks (LLY:NYSE) Seeking Alpha · 3h ago
- Here Is Why AtaiBeckley (ATAI) Is One Of The 10 Best Stocks Under $10 That Could Triple Yahoo Finance · 3h ago
- Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports Reuters · 3h ago
- Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley Bloomberg.com · 3h ago
- ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly Yahoo Finance · 12h ago
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PR Newswire · 12h ago
- Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction CNBC · 12h ago
Topics
Related trends
Uber to buy Germany’s Delivery Hero in $14.8bn global deal
Uber is acquiring Germany-based Delivery Hero in a deal valued at approximately $14.8 billion to establish a global takeout giant.
The F.D.A. Approves a New Pill to Slash Cholesterol Levels
The FDA has approved a first-of-its-kind cholesterol pill from Merck designed to drive cholesterol levels lower than statins.
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
Biogen faces a mixed market reception as new trial data for its tau-targeting Alzheimer's drug shows both promise and significant unanswered questions.
All eyes on data on Biogen’s tau therapy
Biogen's experimental anti-tau therapy, diranersen, shows promise in slowing cognitive decline for early Alzheimer's patients.
FDA releases 14 drug rejection letters after 3-month pause
The FDA has resumed the release of Complete Response Letters (CRLs) after a three-month disclosure freeze, issuing 14 new drug rejection notices.
FDA moves to expose hidden foreign drug factories, strengthen domestic production in sweeping rule proposal
The FDA has introduced a proposal to consolidate registration requirements for distributed drug manufacturing networks, aiming to increase supply chain transparency.